Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ADVM Stock Summary
Top 10 Correlated ETFs
ADVM
In the News
Down -29.25% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)
The heavy selling pressure might have exhausted for Adverum Biotechnologies (ADVM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?
Here is how Adverum Biotechnologies (ADVM) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Turn Pocket Change into Profit: 3 Penny Stocks Ready to Pop
There are plenty of penny stocks ready to pop. However, we have to remember that penny stocks are extremely risky, and can be costly in the end.
Stocks on the Launchpad: The Next 3 Market Sensations
In the current bullish stock market, it's an exhilarating period for savvy investors betting on the upcoming market sensations. The optimism is connected to the S&P 500 shattering the historic 5000 threshold, supported by the U.S. Federal Reserve's bullish projection of 2.9% growth in the first quarter (Q1).
Unleash Massive Returns With These 3 Top Penny Stocks
Despite a recent decline in the leading economic index, the U.S. economy is positioned for a positive future in 2024. Strong employment and robust stock levels contribute to the optimistic outlook.
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024
- Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47 th Annual Meeting of the Macula Society, with company-sponsored webcast on Thursday, February 8, 2024 at 8:00am ET -
Here's Why You Should Invest in Adverum (ADVM) Stock Now
Here, we discuss some reasons why buying Adverum Biotechnologies (AQST) stock now may turn out to be a prudent move.
Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society
REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the initial LUNA preliminary efficacy and safety data will be presented at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024.
Adverum Biotechnologies to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Adverum Biotechnologies will present at the following upcoming investor conferences:
Adverum Biotechnologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
REDWOOD CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Linda Rubinstein, chief financial officer of Adverum Biotechnologies, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023.
ADVM Financial details
ADVM Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0.08 | 0 | 0.36 | |
Net income per share | -1.01 | -1.38 | -1.48 | -1.56 | -11.62 | |
Operating cash flow per share | -0.77 | -0.93 | -1.1 | -1.09 | -9.06 | |
Free cash flow per share | -1.07 | -1.07 | -1.25 | -1.21 | -9.14 | |
Cash per share | 2.59 | 5.05 | 3.11 | 1.87 | 9.57 | |
Book value per share | 2.73 | 5.1 | 3.23 | 1.83 | 8.28 | |
Tangible book value per share | 2.73 | 5.1 | 3.23 | 1.83 | 8.28 | |
Share holders equity per share | 2.73 | 5.1 | 3.23 | 1.83 | 8.28 | |
Interest debt per share | 0.5 | 0.36 | 1.05 | 1.05 | 7.44 | |
Market cap | 7.38B | 9.23B | 1.73B | 575.66M | 75.92M | |
Enterprise value | 7.35B | 9.2B | 1.79B | 614.03M | 75.96M | |
P/E ratio | -114.51 | -78.55 | -11.86 | -3.73 | -0.65 | |
Price to sales ratio | 29.54K | 0 | 230.06 | 0 | 21.09 | |
POCF ratio | -150.18 | -116.4 | -16 | -5.33 | -0.83 | |
PFCF ratio | -107.93 | -101.28 | -14.03 | -4.8 | -0.82 | |
P/B Ratio | 42.21 | 21.25 | 5.46 | 3.17 | 0.91 | |
PTB ratio | 42.21 | 21.25 | 5.46 | 3.17 | 0.91 | |
EV to sales | 29.4K | 0 | 239.24 | 0 | 21.1 | |
Enterprise value over EBITDA | -109.76 | -80.83 | -12.68 | -4.08 | -0.64 | |
EV to operating cash flow | -149.5 | -116 | -16.64 | -5.68 | -0.83 | |
EV to free cash flow | -107.44 | -100.93 | -14.59 | -5.12 | -0.82 | |
Earnings yield | -0.01 | -0.01 | -0.08 | -0.27 | -1.54 | |
Free cash flow yield | -0.01 | -0.01 | -0.07 | -0.21 | -1.21 | |
Debt to equity | 0.18 | 0.07 | 0.33 | 0.59 | 0.9 | |
Debt to assets | 0.14 | 0.06 | 0.23 | 0.35 | 0.43 | |
Net debt to EBITDA | 0.5 | 0.28 | -0.49 | -0.25 | 0 | |
Current ratio | 9.06 | 20.82 | 14.88 | 5.91 | 4.13 | |
Interest coverage | 0 | 0 | 0 | 58.79 | 0 | |
Income quality | 0.76 | 0.67 | 0.74 | 0.7 | 0.78 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 113.5 | 0 | 8.59 | 0 | 13.87 | |
Research and developement to revenue | 161.68 | 0 | 11.89 | 0 | 21.52 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.39 | 0.15 | 0.14 | 0.11 | 0.01 | |
Capex to revenue | -76.99 | 0 | -2.02 | 0 | -0.22 | |
Capex to depreciation | -12.24 | -2.85 | -3.26 | -1.81 | -0.14 | |
Stock based compensation to revenue | 39.6 | 0 | 3.36 | 0 | 4.88 | |
Graham number | 7.86 | 12.59 | 10.38 | 8 | 46.53 | |
ROIC | -0.29 | -0.24 | -0.28 | -0.4 | -0.55 | |
Return on tangible assets | -0.29 | -0.24 | -0.33 | -0.5 | -0.68 | |
Graham Net | 1.84 | 4.48 | 1.9 | 0.59 | 0.69 | |
Working capital | 156.46M | 413.57M | 295.83M | 158.35M | 77.86M | |
Tangible asset value | 174.96M | 434.35M | 316.19M | 181.52M | 83.47M | |
Net current asset value | 128.1M | 386.22M | 193.6M | 63.74M | 13.23M | |
Invested capital | 0.18 | 0.07 | 0.33 | 0.59 | 0.9 | |
Average receivables | 0 | 0 | 2.85M | 2.85M | 0 | |
Average payables | 2.91M | 3.46M | 2.1M | 1.81M | 2.08M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 277.84 | 0 | 0 | |
Days payables outstanding | 0 | 246.67 | 108.99 | 125.13 | 124.23 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 1.31 | 0 | 0 | |
Payables turnover | 0 | 1.48 | 3.35 | 2.92 | 2.94 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.37 | -0.27 | -0.46 | -0.85 | -1.4 | |
Capex per share | -0.3 | -0.14 | -0.15 | -0.12 | -0.08 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0.04 | 0 | 0 | 0 | |
Net income per share | -0.33 | -0.29 | -0.31 | -0.33 | -2.34 | |
Operating cash flow per share | -0.19 | -0.22 | -0.23 | -0.24 | -2.11 | |
Free cash flow per share | -0.19 | -0.22 | -0.23 | -0.24 | -2.13 | |
Cash per share | 1.87 | 1.64 | 1.4 | 1.16 | 9.54 | |
Book value per share | 1.83 | 1.57 | 1.3 | 1.02 | 8.25 | |
Tangible book value per share | 1.83 | 1.57 | 1.3 | 1.02 | 8.25 | |
Share holders equity per share | 1.83 | 1.57 | 1.3 | 1.02 | 8.25 | |
Interest debt per share | 1.89 | 0.96 | 0.9 | 0.75 | 7.41 | |
Market cap | 575.66M | 719.18M | 1.6B | 1.51B | 76.21M | |
Enterprise value | 614.03M | 749.24M | 1.58B | 1.49B | 76.25M | |
P/E ratio | -4.4 | -6.19 | -12.71 | -11.52 | -0.8 | |
Price to sales ratio | 0 | 199.77 | 0 | 0 | 0 | |
POCF ratio | -31.16 | -32.09 | -68.92 | -63.35 | -3.56 | |
PFCF ratio | -30.85 | -31.97 | -68.81 | -62.07 | -3.53 | |
P/B Ratio | 3.17 | 4.56 | 12.22 | 14.75 | 0.91 | |
PTB ratio | 3.17 | 4.56 | 12.22 | 14.75 | 0.91 | |
EV to sales | 0 | 208.12 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -19.05 | -26.15 | -50.18 | -44.98 | -3.06 | |
EV to operating cash flow | -33.24 | -33.43 | -68.05 | -62.11 | -3.56 | |
EV to free cash flow | -32.91 | -33.3 | -67.95 | -60.85 | -3.53 | |
Earnings yield | -0.06 | -0.04 | -0.02 | -0.02 | -0.31 | |
Free cash flow yield | -0.03 | -0.03 | -0.01 | -0.02 | -0.28 | |
Debt to equity | 0.59 | 0.62 | 0.69 | 0.74 | 0.9 | |
Debt to assets | 0.35 | 0.35 | 0.38 | 0.38 | 0.43 | |
Net debt to EBITDA | -1.19 | -1.05 | 0.64 | 0.9 | 0 | |
Current ratio | 5.91 | 3.63 | 3.31 | 4.32 | 4.13 | |
Interest coverage | -0.42 | 25.2 | 0 | 0 | 0 | |
Income quality | 0.56 | 0.77 | 0.74 | 0.73 | 0.9 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 3.55 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 5.85 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0 | 0 | 0.02 | 0.01 | |
Capex to revenue | 0 | -0.02 | 0 | 0 | 0 | |
Capex to depreciation | -0.11 | -0.05 | -0.02 | -0.33 | -0.19 | |
Stock based compensation to revenue | 0 | 1.27 | 0 | 0 | 0 | |
Graham number | 3.68 | 3.2 | 3.03 | 2.73 | 20.85 | |
ROIC | -0.09 | -0.09 | -0.11 | -0.14 | -0.11 | |
Return on tangible assets | -0.11 | -0.11 | -0.13 | -0.17 | -0.14 | |
Graham Net | 0.59 | 0.46 | 0.31 | 0.23 | 0.69 | |
Working capital | 158.35M | 122.4M | 102.63M | 95.74M | 77.86M | |
Tangible asset value | 181.52M | 157.76M | 131.16M | 102.71M | 83.47M | |
Net current asset value | 63.74M | 51.05M | 36.87M | 30.54M | 13.23M | |
Invested capital | 0.59 | 0.62 | 0.69 | 0.74 | 0.9 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 1.54M | 2.55M | 2.14M | 1.79M | 2.05M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 117.65 | 85.35 | 18.12 | 129.42 | 171.35 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.76 | 1.05 | 4.97 | 0.7 | 0.53 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.18 | -0.18 | -0.24 | -0.32 | -0.28 | |
Capex per share | 0 | 0 | 0 | 0 | -0.02 |
ADVM Frequently Asked Questions
What is Adverum Biotechnologies, Inc. stock symbol ?
Adverum Biotechnologies, Inc. is a US stock , located in Redwood city of Ca and trading under the symbol ADVM
Is Adverum Biotechnologies, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $2. The lowest prediction is $2 and the highest is $2
What is ADVM stock prediction ?
What is Adverum Biotechnologies, Inc. stock quote today ?
Adverum Biotechnologies, Inc. stock price is $14.66 today.
Is Adverum Biotechnologies, Inc. stock public?
Yes, Adverum Biotechnologies, Inc. is a publicly traded company.